The Evolving Treatment Landscape for Myelofibrosis

Naveen Pemmaraju, MD, explains the types of myeloproliferative neoplasms, the currently available treatment options, and how treatment approaches have changed historically.

EP. 1: Overview of the Types of Myeloproliferative Neoplasms

August 18th 2022

Naveen Pemmaraju, MD, provides an overview of the three classes of myeloproliferative neoplasms and the signaling pathways that drive therapeutic investigation in the field.

EP. 2: Current Standards of Care for Polycythemia Vera and Essential Thrombocytosis

August 18th 2022

Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.

EP. 3: Overview of Myelofibrosis and the Challenges of Diagnosis

August 18th 2022

An expert gives an overview of myelofibrosis and its different types and describes the common challenges of diagnosing patients.

EP. 4: Approved Systemic Treatment Options for Myelofibrosis

August 18th 2022

Naveen Pemmaraju, MD, reviews the currently approved systemic treatment options for myelofibrosis and explains how he decides between treatment regimens.

EP. 5: Ruxolitinib Combination Therapies for Myeloproliferative Neoplasms

August 18th 2022

Dr Pemmaraju explains the rationale for ruxolitinib combination therapies in myeloproliferative neoplasm treatment.

EP. 6: Single-Agent Investigational Therapies for Myeloproliferative Neoplasms

August 18th 2022

A key opinion leader details the single-agent therapies currently being investigated for the treatment of myeloproliferative neoplasms.

EP. 7: Major Unmet Needs in Myeloproliferative Neoplasm Management

August 18th 2022

Naveen Pemmaraju, MD, shares the critical unmet needs in the myeloproliferative neoplasm treatment landscape.